TherapeuticsMD, Inc. (NASDAQ:TXMD), a pharmaceutical company, has announced an updated deadline for shareholder proposals for its upcoming 2024 Annual Meeting of Stockholders. The meeting is scheduled for December 5, 2024, with stockholders of record as of October 17, 2024, eligible to vote.
The announcement, made today, follows the realization that the 2024 Annual Meeting date deviates by more than thirty days from the anniversary of the previous year's meeting. Consequently, previous deadlines for submitting shareholder proposals are no longer valid.
Shareholders looking to submit proposals under Rule 14a-8 of the Exchange Act must send their written proposals to the company by September 30, 2024. This new deadline allows the company reasonable time to include such proposals in its proxy materials. All submissions must adhere to SEC rules, including those specified in Rule 14a-8.
Additionally, shareholders intending to nominate directors or present other matters at the meeting must provide written notice to TherapeuticsMD by September 30, 2024. This date marks ten days following the public announcement of the 2024 Annual Meeting date. The company's bylaws outline further requirements for the advance notice of stockholder proposals and director nominations.
InvestingPro Insights
As TherapeuticsMD prepares for its 2024 Annual Meeting of Stockholders, investors may consider the company's current financial health and market standing. According to recent data from InvestingPro, TherapeuticsMD has a market capitalization of approximately $19.49 million. Despite a challenging period with a revenue decline of 98.57% over the last twelve months as of Q2 2024, analysts are expecting an improvement in the company's financials. They anticipate sales growth and predict that the company will become profitable within the current year. This is particularly notable as the company has not been profitable over the past twelve months. Additionally, TherapeuticsMD operates with a moderate level of debt and is trading at a high revenue valuation multiple.
Investors may also observe the company's stock price performance, which has seen a significant drop of 47.08% over the past year. However, the InvestingPro Fair Value estimate stands at $1.79, slightly above the previous close price of $1.72. These metrics, alongside the expected growth in net income and sales, could be indicative of the company's potential turnaround and future prospects.
For those interested in a deeper analysis, InvestingPro offers additional insights and metrics on TherapeuticsMD, which can be accessed on their platform. There are seven more InvestingPro Tips available that could guide investors in making more informed decisions regarding their investments in TXMD.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.